Sugi Predict

Sugi Predict / Compounds / SCHEMBL7180182

SCHEMBL7180182

SCHEMBL7180182

Cc1cc(C)c(C(=O)P(=O)(C(=O)c2c(C)cc(C(C)(C)C)cc2C)c2ccccc2)c(C)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.40
▸ RXRB P28702 4/20 0.39
▸ RXRA P19793 3/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ KCNK9 Q9NPC2 1/20 0.35
▸ TSHR P16473 2/20 0.35
▸ MAPT P10636 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ PPARG P37231 1/20 0.34
▸ PPARA Q07869 1/20 0.34
▸ NR1H4 Q96RI1 1/20 0.34
▸ STAT5B P51692 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7187514 0.95 LMNA (0.40) LMNARXRBRXRAL3MBTL1KCNK9
SCHEMBL7189845 0.93 LMNA (0.37) LMNARXRBRXRAL3MBTL1KDM4E
SCHEMBL7182360 0.91 TP53 (0.39) LMNARXRBRXRAL3MBTL1KCNK9
SCHEMBL15158 0.91 LMNA (0.40) LMNAMAPTMEN1KMT2ANPC1
SCHEMBL7179675 0.90 LMNA (0.37) LMNARXRBRXRAL3MBTL1KDM4E
SCHEMBL25250816 0.89 LMNA (0.39) LMNAMAPTMEN1KMT2ANPC1
SCHEMBL30988127 0.89 KMT2A (0.41) LMNAMAPTMEN1KMT2ANPC1
Iodide SCHEMBL29831346 0.89 LMNA (0.39) LMNAMAPTMEN1KMT2ANPC1
Lithium SCHEMBL30307090 0.89 LMNA (0.39) LMNAMAPTMEN1KMT2ANPC1
Ammonia Solution, Strong SCHEMBL28286046 0.89 LMNA (0.40) LMNAMAPTMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 LMNA 3241/4885RXRB 3027/4885RXRA 2745/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 LMNA 3247/4885RXRB 3240/4885RXRA 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.